The Clinical Significance of JAK2V617F Mutational Status on Phenotypic Features in Philadelphia-Negative Chronic Myeloproliferative Neoplasms

被引：0
|
作者：
Sahin, Ezgi [1 ]
Yonal-Hindilerden, Ipek [1 ]
Hindilerden, Fehmi [2 ]
Daglar-Aday, Aynur [3 ]
Nalcaci, Meliha [1 ]
机构：
[1] Istanbul Univ, Div Hematol, Dept Internal Med, Istanbul Med Fac, Istanbul, Turkey
[2] Univ Hlth Sci Bakirkoy Dr Sadi Konuk Training & R, Hematol Clin, Istanbul, Turkey
[3] Istanbul Univ, Div Med Genet, Dept Internal Med, Istanbul Med Fac, Istanbul, Turkey
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2020年 / 20卷
关键词：
JAK2V16F mutation; polycythemia vera; essential thrombocythemia; primary myelofibrosis; MPN;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-364
引用
收藏
页码：S337 / S338
页数：2
相关论文
共 50 条
  • [41] Identification of JAK2V617F Mutation on Myeloproliferative Disorders in Medan
    Anggraini, Dwi Rita
    Hidayat
    Sitorus, Mega Sari
    PROCEEDINGS OF THE 1ST PUBLIC HEALTH INTERNATIONAL CONFERENCE (PHICO 2016), 2016, 1
  • [42] JAK2 inhibitors for the treatment of Philadelphia-negative myeloproliferative neoplasms: current status and future directions
    Liu, Xiaofeng
    Wang, Binyou
    Liu, Yuan
    Yu, Yang
    Wan, Ying
    Wu, Jianming
    Wang, Yiwei
    MOLECULAR DIVERSITY, 2024, 28 (05) : 3445 - 3456
  • [43] Contributions of bone marrow monocytes/macrophages in myeloproliferative neoplasms with JAK2V617F mutation
    Fan, Wenjuan
    Cao, Weijie
    Shi, Jianxiang
    Gao, Fengcai
    Wang, Meng
    Xu, Linping
    Wang, Fang
    Li, Yingmei
    Guo, Rong
    Bian, Zhilei
    Li, Wei
    Jiang, Zhongxing
    Ma, Wang
    ANNALS OF HEMATOLOGY, 2023, 102 (07) : 1745 - 1759
  • [44] Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2V617F mutation
    Guy, Alexandre
    Helzy, Khalil
    Mansier, Olivier
    Bordet, Jean-Claude
    Riviere, Etienne
    Fiore, Mathieu
    James, Chloe
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (02)
  • [45] Interferon-Alpha in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Status and Perspectives
    Hasselbalch, Hans Carl
    Larsen, Thomas Stauffer
    Riley, Caroline Hasselbalch
    Jensen, Morten Krogh
    Kiladjian, Jean-Jacques
    CURRENT DRUG TARGETS, 2011, 12 (03) : 392 - 419
  • [46] Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
    Tibes, Raoul
    Mesa, Ruben A.
    LEUKEMIA & LYMPHOMA, 2011, 52 (07) : 1178 - 1187
  • [47] Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
    Grzegorz Helbig
    Medical Oncology, 2018, 35
  • [48] Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
    Helbig, Grzegorz
    MEDICAL ONCOLOGY, 2018, 35 (09)
  • [49] Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice
    Kaiyao Shi
    Wanke Zhao
    Yun Chen
    Wanting Tina Ho
    Ping Yang
    Zhizhuang Joe Zhao
    Journal of Hematology & Oncology, 7
  • [50] Targeting PAR1 activation in JAK2V617F-driven philadelphia-negative myeloproliferative neoplasms: Unraveling its role in thrombosis and disease progression
    Uslu-bicak, Ildeniz
    Nalcaci, Meliha
    Soezer, Selcuk
    NEOPLASIA, 2025, 63
12345